DK1572931T3 - Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet - Google Patents

Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet

Info

Publication number
DK1572931T3
DK1572931T3 DK03739341.0T DK03739341T DK1572931T3 DK 1572931 T3 DK1572931 T3 DK 1572931T3 DK 03739341 T DK03739341 T DK 03739341T DK 1572931 T3 DK1572931 T3 DK 1572931T3
Authority
DK
Denmark
Prior art keywords
wisp
modulating
compositions
methods
activity
Prior art date
Application number
DK03739341.0T
Other languages
English (en)
Inventor
Luc Desnoyer
Ellen Filvaroff
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1572931T3 publication Critical patent/DK1572931T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK03739341.0T 2002-06-29 2003-06-28 Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet DK1572931T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39265202P 2002-06-29 2002-06-29
US40873902P 2002-09-06 2002-09-06
PCT/US2003/020407 WO2004003158A2 (en) 2002-06-29 2003-06-28 Methods and compositions for modulating and detecting wisp activity

Publications (1)

Publication Number Publication Date
DK1572931T3 true DK1572931T3 (da) 2010-11-08

Family

ID=30003268

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03739341.0T DK1572931T3 (da) 2002-06-29 2003-06-28 Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet

Country Status (10)

Country Link
US (1) US7456262B2 (da)
EP (1) EP1572931B1 (da)
JP (1) JP4636497B2 (da)
AT (1) ATE476447T1 (da)
AU (1) AU2003245733B2 (da)
CA (1) CA2489515C (da)
DE (1) DE60333669D1 (da)
DK (1) DK1572931T3 (da)
IL (1) IL165776A (da)
WO (1) WO2004003158A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JP4636497B2 (ja) 2002-06-29 2011-02-23 ジェネンテック， インコーポレイテッド Ｗｉｓｐ活性を調節し検出するための方法及び組成物
AU2004272066B8 (en) * 2003-09-11 2010-08-05 Genentech, Inc. Methods of using WISP antagonists
US8460658B2 (en) 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
DK1678194T3 (da) * 2003-10-10 2013-10-07 Alchemia Oncology Pty Ltd Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
EP1736173B1 (en) * 2004-03-31 2018-02-28 Two Cells Co., Ltd Damaged tissue therapeutic agent and therapeutic method
CN113087772B (zh) * 2021-04-27 2022-04-22 清华大学深圳国际研究生院 一种rhamm拮抗多肽及其衍生物与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1288399A (en) 1997-10-29 1999-05-17 Genentech Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
ATE364628T1 (de) 1999-03-08 2007-07-15 Genentech Inc Verfahren und zusammensetzungen zur diagnose von tumoren
JP4636497B2 (ja) 2002-06-29 2011-02-23 ジェネンテック， インコーポレイテッド Ｗｉｓｐ活性を調節し検出するための方法及び組成物
AU2004272066B8 (en) 2003-09-11 2010-08-05 Genentech, Inc. Methods of using WISP antagonists

Also Published As

Publication number Publication date
EP1572931A4 (en) 2006-03-01
DE60333669D1 (de) 2010-09-16
IL165776A (en) 2010-06-30
WO2004003158A2 (en) 2004-01-08
IL165776A0 (en) 2006-01-15
ATE476447T1 (de) 2010-08-15
US7456262B2 (en) 2008-11-25
CA2489515C (en) 2013-01-22
EP1572931A2 (en) 2005-09-14
JP4636497B2 (ja) 2011-02-23
JP2006516956A (ja) 2006-07-13
US20060073135A1 (en) 2006-04-06
WO2004003158A3 (en) 2005-08-04
CA2489515A1 (en) 2004-01-08
AU2003245733B2 (en) 2009-11-26
EP1572931B1 (en) 2010-08-04
AU2003245733A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
NO20050685L (no) NOGO-reseptorantagonister
DE60325892D1 (de) Stellungs- und verwendungsverfahren
IS8339A (is) Mótlyf viðtaka NOGO
DK1140173T3 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
HK1077592A1 (zh) 改進型fc融合蛋白質
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1572931T3 (da) Fremgangsmåder og sammensætninger til modulering og påvisning af WISP-aktivitet
NO20075825L (no) Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
DE60221501D1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
CY1116637T1 (el) Πολυπεπτιδια συντηξης igf-1 και θεραπευτικες χρησεις αυτων
DE60044136D1 (de) Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung
DE60238243D1 (de) Polypeptide, abgeleitet von der amyloid vorläuferprotein (app), und ihre verwendungen
ATE329025T1 (de) Mfq-111, ein menschliches gtpase-ähnlichers protein